Company: EDSA
Filing Date: 2025-07-25
Form Type: S-3
Source: 0001171843-25-004721
Chunk: 10

Company: Edesa Biotech, Inc.
Filing Date: 2025-07-25
Form: S-3
Chunk 10
---
, for each series; (iii) the price at which, and the terms and conditions on which, the preferred shares of each series may be redeemed, if such shares are redeemable; (iv) the terms and conditions, if any, upon which preferred shares of such series may be converted into shares of other classes or series of shares of the Company, or other securities; and (v) the maturity date, if any, for each such series; but no such special rights or restriction shall contravene any other provision of Part 26 of our Articles.

We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, a Notice of Alteration to the Notice of Articles of the Company, which will be filed in accordance with British Columbia law and which shall describe the designations, preferences, limitations, restrictions and rights of the series of preferred shares that we are offering before the issuance of that series of preferred shares. This description will include:

|  | the title and stated value; |

|  | the number of shares we are offering; |

|  | the liquidation preference per share; |

|  | the purchase price; |

|  | the rate and amount of dividends (whether cumulative, non-cumulative or partially cumulative), 
 the dates and places of payment thereof;                                                       |

|  | the consideration for, and the terms and conditions of, any purchase for cancellation 
 or redemption thereof (including redemption after a fixed term or at a premium);      |

|  | the conversion or exchange rights; |

| 7 |

|  | the terms and conditions of any share purchase plan or sinking fund; |

|  | the restrictions respecting payment of dividends on, or the repayment of capital in respect 
 of, any other share of the Company;                                                         |

|  | the voting rights and restrictions, if any; |

|  | any listing of the preferred shares on any securities exchange or market; |

|  | whether the preferred shares will be convertible into our common shares, and, if applicable, 
 the conversion price, or how it will be calculated, and the conversion period;               |

|  | preemptive rights, if any; |

|  | restrictions on transfer, sale or other assignment, if any; |

|  | whether interests in the preferred shares will be represented by depositary shares; |

| �